Danaher Co. (NYSE:DHR) Shares Sold by Bank of New Hampshire

Bank of New Hampshire reduced its position in Danaher Co. (NYSE:DHR) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,921 shares of the conglomerate’s stock after selling 443 shares during the period. Bank of New Hampshire’s holdings in Danaher were worth $1,130,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. FMR LLC lifted its stake in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the period. Legal & General Group Plc lifted its stake in shares of Danaher by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after purchasing an additional 139,989 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after purchasing an additional 148,251 shares during the period. Fisher Asset Management LLC lifted its stake in shares of Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after purchasing an additional 116,299 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Up 1.8 %

Shares of DHR traded up $4.27 during mid-day trading on Tuesday, reaching $242.47. The stock had a trading volume of 210,212 shares, compared to its average volume of 2,244,948. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 52-week low of $222.53 and a 52-week high of $281.70. The business’s fifty day moving average is $236.25 and its 200 day moving average is $254.22. The firm has a market cap of $175.13 billion, a price-to-earnings ratio of 46.27, a P/E/G ratio of 4.33 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the company posted $2.02 earnings per share. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, sell-side analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s payout ratio is currently 20.61%.

Wall Street Analyst Weigh In

DHR has been the subject of several recent analyst reports. Stifel Nicolaus boosted their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a report on Friday, December 13th. Raymond James cut their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. UBS Group cut their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.